Irofulvene in Treating Patients With Stage III or Stage IV Pancreatic Cancer
Status:
Completed
Trial end date:
2000-05-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so
they stop growing or die.
PURPOSE: Phase II trial to study the effectiveness of irofulven in treating patients who have
stage III or stage IV pancreatic cancer that cannot be surgically removed.
Phase:
Phase 2
Details
Lead Sponsor:
The University of Texas Health Science Center at San Antonio
Collaborators:
Merck Sharp & Dohme Corp. National Cancer Institute (NCI) University of Texas